Scarica l'app Stockscreener
1.05
2.78%
-0.03
Dopo l'orario di chiusura:
1.04
-0.01
-0.95%
Jupiter Neurosciences Inc Borsa (JUNS) Ultime notizie
Jupiter Neurosciences’ Innovative Strategy in Biotech: A Dual Approach to Success - citybuzz -
How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success - FinancialContent
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Jupiter Neurosciences launches Nugevia longevity products By Investing.com - Investing.com South Africa
Jupiter Neurosciences launches resveratrol-powered supplements - Longevity.Technology
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Jupiter Neurosciences launches Nugevia longevity products - Investing.com
Jupiter Neurosciences Launches Nugevia™: A Premium - GlobeNewswire
Jupiter Neurosciences Targets $8T Longevity Market with Revolutionary 9x More Effective Supplement Line - Stock Titan
IsoEnergy Announces Launch of At-The-Market Equity Program - The Globe and Mail
Certain Restricted Stock Units of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Certain Common Stock of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Certain Options of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
Jupiter Neurosciences appoints new auditor amid transition By Investing.com - Investing.com Nigeria
Jupiter Neurosciences appoints new auditor amid transition - Investing.com Australia
Jupiter Neurosciences targets Parkinson’s and longevity markets By Investing.com - Investing.com South Africa
Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development - marketscreener.com
Jupiter Neurosciences targets Parkinson's and longevity markets - Investing.com
Jupiter's Super-Resveratrol Targets Parkinson's Trial and $16.5M NIH Grant - Stock Titan
Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz
Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com India
Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph
Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire
Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks
Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa
Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com
Jupiter Neurosciences partners with Aquanova on health products - Investing.com
Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan
Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater
Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria
Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire
Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Clinical Trials News Live Feed - StockTitan
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today
Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire
Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa
1.11%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):